---
layout: default
title: An Antibody Enclycopedia
---
## FDA Approved Antibodies

| OfficialName | Name | Target | Indication | Original Approval |
|---|---|---|---|---|
| [ORTHOCLONE_OKT3](../wiki/ORTHOCLONE_OKT3) | Muromonab-CD3 | CD3 | Transplants | 1985 |
| [CEA-SCAN](../wiki/CEA-SCAN) | Arcitumomab | CD66 (CEA) | Cancer | 1996 |
| [MYLOTARG](../wiki/MYLOTARG) | Gemtuzumab-ozogamicin | CD33 | Cancer | 1996 |
| [PROSTASCINT](../wiki/PROSTASCINT) | Capromabpendetide | PSMA | Cancer | 1996 |
| [VERLUMA](../wiki/VERLUMA) | Nofetumomab-merpentan | Glycoprotein (EpCAM;CD20) | Cancer | 1996 |
| [REOPRO](../wiki/REOPRO) | Abciximab | CD41 (Integrin alpha-IIb) |  | 1997 |
| [RITUXAN](../wiki/RITUXAN) | Rituximab | CD20 | Autoimmunity; Cancer | 1997 |
| [ZENPAX](../wiki/ZENPAX) | Daclizumab | CD25 (α chain of IL-2R) | Transplants | 1997 |
| [ENBREL](../wiki/ENBREL) | Etanercept | TNFα | Autoimmunity | 1998 |
| [HERCEPTIN](../wiki/HERCEPTIN) | Trastuzumab | CD340 (HER2) | Cancer | 1998 |
| [REMICADE](../wiki/REMICADE) | Infliximab | TNFα | Autoimmunity | 1998 |
| [SIMULECT](../wiki/SIMULECT) | Basiliximab | CD25 (α chain of IL-2R) | Transplants | 1998 |
| [SYNAGIS](../wiki/SYNAGIS) | Palivizumab | F protein of RSV | Viral Infection | 1998 |
| [LEMTRADA](../wiki/LEMTRADA) | Alemtuzumab | CD52 | Cancer | 2001 |
| [CAMPATH](../wiki/CAMPATH) | Alemtuzumab | CD52 | Autoimmunity | 2001 |
| [HUMIRA](../wiki/HUMIRA) | Adalimumab | TNFα | Autoimmunity | 2002 |
| [ZEVALIN](../wiki/ZEVALIN) | Ibritumomab-tiuxetan | CD20 | Cancer | 2002 |
| [AMEVIVE](../wiki/AMEVIVE) | Alefacept | CD2 | Autoimmunity | 2003 |
| [BEXXAR](../wiki/BEXXAR) | Tositumomab | CD20 | Cancer | 2003 |
| [RAPTIVA](../wiki/RAPTIVA) | Efalizumab | CD11a (LFA-1) | Autoimmunity | 2003 |
| [XOLAIR](../wiki/XOLAIR) | Omalizumab | IgE Fc region | Autoimmunity | 2003 |
| [AVASTIN](../wiki/AVASTIN) | Bevacizumab | VEGF-A | Cancer | 2004 |
| [ERBITUX](../wiki/ERBITUX) | Cetuximab | EGFR | Cancer | 2004 |
| [TYSABRI](../wiki/TYSABRI) | Natalizumab | integrin α4 | Autoimmunity | 2004 |
| [ORENCIA](../wiki/ORENCIA) | Abatacept | CD80; CD86 | Autoimmunity | 2005 |
| [LUCENTIS](../wiki/LUCENTIS) | Ranibizumabd | VEGF-A |  | 2006 |
| [VECTIBIX](../wiki/VECTIBIX) | Panitumumab | EGFR | Cancer | 2006 |
| [SOLIRIS](../wiki/SOLIRIS) | Eculizumab | C5 |  | 2007 |
| [ARCALYST](../wiki/ARCALYST) | Rilonacept | IL-1 |  | 2008 |
| [CIMZIA](../wiki/CIMZIA) | Certolizumab-pegol | TNFα | Autoimmunity | 2008 |
| [NPLATE](../wiki/NPLATE) | Romiplostim | CD110 (Thrombopoietin receptor) |  | 2008 |
| [ARZERRA](../wiki/ARZERRA) | Ofatumumab | CD20 | Cancer | 2009 |
| [ILARIS](../wiki/ILARIS) | Canakinumab | IL-1b |  | 2009 |
| [REMOVAB](../wiki/REMOVAB) | Catumaxomab | EpCAM | Cancer | 2009 EMA |
| [SIMPONI](../wiki/SIMPONI) | Golimumab | TNFα | Autoimmunity | 2009 |
| [SIMPONI_ARIA](../wiki/SIMPONI_ARIA) | Golimumab | TNFα | Autoimmunity | 2009 |
| [STELARA](../wiki/STELARA) | Ustekinumab | IL-12; IL-23 | Autoimmunity | 2009 |
| [ACTEMRA](../wiki/ACTEMRA) | Tocilizumab | CD126 (IL-6R) | Autoimmunity | 2010 |
| [PROLIA](../wiki/PROLIA) | Denosumab | CD254 (RANKL) |  | 2010 |
| [XGEVA](../wiki/XGEVA) | Denosumab | CD254 (RANKL) | Cancer | 2010 |
| [ADCETRIS](../wiki/ADCETRIS) | Brentuximab-vedotin | CD30 (TNFRSF8) | Cancer | 2011 |
| [BENLYSTA](../wiki/BENLYSTA) | Belimumab | CD257 (BAFF) | Autoimmunity | 2011 |
| [NULOJIX](../wiki/NULOJIX) | Belatacept | CD80; CD86 | Transplants | 2011 |
| [YERVOY](../wiki/YERVOY) | Ipilimumab | CD152 (CTLA-4) | Cancer | 2011 |
| [PERJETA](../wiki/PERJETA) | Pertuzumab | CD340 (HER2) | Cancer | 2012 |
| [RAXIBACUMAB](../wiki/RAXIBACUMAB) | Raxibacumab | anthrax toxin; protective antigen | Fungal Infection | 2012 |
| [GAZYVA](../wiki/GAZYVA) | Obinutuzumab | CD20 | Cancer | 2013 |
| [KADCYLA](../wiki/KADCYLA) | Ado-Trastuzumab-emtansine | CD340 (HER2) | Cancer | 2013 |
| [BLINCYTO](../wiki/BLINCYTO) | Blinatumomab | CD19 | Cancer | 2014 |
| [CYRAMZA](../wiki/CYRAMZA) | Ramucirumab | VEGFR2 | Cancer | 2014 |
| [ENTYVIO](../wiki/ENTYVIO) | Vedolizumab | Integrin α4β7 | Autoimmunity | 2014 |
| [KEYTRUDA](../wiki/KEYTRUDA) | Pembrolizumab | CD279 (PD-1) | Cancer | 2014 |
| [OPDIVO](../wiki/OPDIVO) | Nivolumab | CD279 (PD-1) | Cancer | 2014 |
| [SYLVANT](../wiki/SYLVANT) | Siltuximab | IL-6 |  | 2014 |
| [COSENTYX](../wiki/COSENTYX) | Secukinumab | IL-17α | Autoimmunity | 2015 |
| [DARZALEX](../wiki/DARZALEX) | Daratumumab | CD38 | Cancer | 2015 |
| [EMPLICITI](../wiki/EMPLICITI) | Elotuzumab | CD319 (SLAMF7) | Cancer | 2015 |
| [NUCALA](../wiki/NUCALA) | Mepolizumab | IL-5 | Autoimmunity | 2015 |
| [PORTRAZZA](../wiki/PORTRAZZA) | Necitumumab | EGFR | Cancer | 2015 |
| [PRALUENT](../wiki/PRALUENT) | Alirocumab | PCSK9 |  | 2015 |
| [PRAXBIND](../wiki/PRAXBIND) | Idarucizumab | Dabigatran |  | 2015 |
| [REPATHA](../wiki/REPATHA) | Evolocumab | PCSK9 |  | 2015 |
| [UNITUXIN](../wiki/UNITUXIN) | Dinutuximab | GD2 ganglioside | Cancer | 2015 |
| [ZINBRYTA](../wiki/ZINBRYTA) | Daclizumab | CD25 (α chain of IL-2R) | Autoimmunity | 2016 |
| [AMJEVITA](../wiki/AMJEVITA) | Adalimumab-Atto | TNFα | Autoimmunity | 2016 |
| [ANTHIM](../wiki/ANTHIM) | Obiltoxaximab | Bacillus anthracis anthrax | Bacterial Infection | 2016 |
| [CINQUAIR](../wiki/CINQUAIR) | Reslizumab | IL-5 | Autoimmunity | 2016 |
| [INFLECTRA](../wiki/INFLECTRA) | Infliximab-dyyb | TNFα | Autoimmunity | 2016 |
| [LARTRUVO](../wiki/LARTRUVO) | Olaratumab | PDGF-Rα | Cancer | 2016 |
| [TALTZ](../wiki/TALTZ) | Ixekizumab | IL-17α | Autoimmunity | 2016 |
| [TECENTRIQ](../wiki/TECENTRIQ) | Atezolizumab | CD274 (PD-L1) | Cancer | 2016 |
| [ZINPLAVA](../wiki/ZINPLAVA) | Bezlotoxumab | Clostridium difficile Toxin B | Bacterial Infection | 2016 |
| [BAVENCIO](../wiki/BAVENCIO) | Avelumab | CD274 (PD-L1) | Cancer | 2017 |
| [DUPIXENT](../wiki/DUPIXENT) | Dupliumab | IL-4Rα | Autoimmunity | 2017 |
| [OCREVUS](../wiki/OCREVUS) | Ocrelizumab | CD20 | Autoimmunity | 2017 |
| [SILIQ](../wiki/SILIQ) | Brodalumab | IL-17R | Autoimmunity | 2017 |
| [MVASI](../wiki/MVASI) | bevacizumab-awwb | VEGF-A | Cancer | 2017 |
| [BESPONSA](../wiki/BESPONSA) | Inotuzumab-ozogamicin | CD22 | Cancer | 2017 |
| [CYLTEZO](../wiki/CYLTEZO) | Adalimumab-Adbm | TNFα | Autoimmunity | 2017 |
| [IMFINZI](../wiki/IMFINZI) | Durvalumab | CD274 (PD-L1) | Cancer | 2017 |
| [KEVZARA](../wiki/KEVZARA) | Sarilumab | CD126 (IL-6R) | Autoimmunity | 2017 |
| [RENFLEXIS](../wiki/RENFLEXIS) | Infliximab-abda | TNFα | Autoimmunity | 2017 |
| [RITUXAN_HYCELA](../wiki/RITUXAN_HYCELA) | Rituximab-hyaluronidase | CD20 | Cancer | 2017 |
| [TREMFYA](../wiki/TREMFYA) | Guselkumab | IL-23α | Autoimmunity | 2017 |
| [](../wiki/) |  |  |  |  |
| [](../wiki/) |  |  |  |  |
| [](../wiki/) |  |  |  |  |
